Kali Therapeutics Partners with Sanofi on Advanced T-Cell Therapy Targeting Autoimmune Disorders Kali Therapeutics has secured an exclusive license agreement with Sanofi to advance its innovative T-cell engager, KT501, targeting autoimmune diseases. This collaboration aims to enhance treatment options.

Kali Therapeutics Partners with Sanofi on Advanced T-Cell Therapy Targeting Autoimmune Disorders #USA #San_Mateo #Sanofi #Kali_Therapeutics #KT501

Kali Therapeutics Makes Strides in Autoimmune Research with KT501 Trial Kali Therapeutics has announced the successful dosing of the first patient in its Phase 1a trial for KT501, a promising treatment for rheumatoid arthritis.

Kali Therapeutics Makes Strides in Autoimmune Research with KT501 Trial #United_States #San_Mateo #rheumatoid_arthritis #Kali_Therapeutics #KT501